Trial to Evaluate Safety and Tolerability of ALN-TTR01 in Transthyretin (TTR) Amyloidosis
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics and
pharmacodynamics of a single dose of ALN-TTR01 in patients with transthyretin (TTR) mediated
amyloidosis (ATTR).